These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7893988)

  • 1. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.
    Suhadolnik RJ; Reichenbach NL; Hitzges P; Adelson ME; Peterson DL; Cheney P; Salvato P; Thompson C; Loveless M; Müller WE
    In Vivo; 1994; 8(4):599-604. PubMed ID: 7893988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome.
    Suhadolnik RJ; Reichenbach NL; Hitzges P; Sobol RW; Peterson DL; Henry B; Ablashi DV; Müller WE; Schröder HC; Carter WA
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S96-104. PubMed ID: 8148461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA drug therapy acting via the 2-5A synthetase/RNase L pathway.
    Suhadolnik RJ; Reichenbach NL; Hitzges PM; Ablashi DV; Strayer DR; Carter WA
    Ann N Y Acad Sci; 1993 Jun; 685():756-7. PubMed ID: 8363281
    [No Abstract]   [Full Text] [Related]  

  • 4. Mode of action of the anti-AIDS compound poly(I).poly(C12U) (Ampligen): activator of 2',5'-oligoadenylate synthetase and double-stranded RNA-dependent kinase.
    Ushijima H; Rytik PG; Schäcke H; Scheffer U; Müller WE; Schröder HC
    J Interferon Res; 1993 Apr; 13(2):161-71. PubMed ID: 8099601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.
    Strayer DR; Carter WA; Brodsky I; Cheney P; Peterson D; Salvato P; Thompson C; Loveless M; Shapiro DE; Elsasser W
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S88-95. PubMed ID: 8148460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome.
    Suhadolnik RJ; Peterson DL; O'Brien K; Cheney PR; Herst CV; Reichenbach NL; Kon N; Horvath SE; Iacono KT; Adelson ME; De Meirleir K; De Becker P; Charubala R; Pfleiderer W
    J Interferon Cytokine Res; 1997 Jul; 17(7):377-85. PubMed ID: 9243369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 8-Azido double-stranded RNA photoaffinity probes. Enzymatic synthesis, characterization, and biological properties of poly(I,8-azidoI).poly(C) and poly(I,8-azidoI).poly(C12U) with 2',5'-oligoadenylate synthetase and protein kinase.
    Li SW; Moskow JJ; Suhadolnik RJ
    J Biol Chem; 1990 Apr; 265(10):5470-4. PubMed ID: 2318823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers.
    Hendrix CW; Margolick JB; Petty BG; Markham RB; Nerhood L; Farzadegan H; Ts'o PO; Lietman PS
    Antimicrob Agents Chemother; 1993 Mar; 37(3):429-35. PubMed ID: 7681656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.
    Vojdani A; Choppa PC; Lapp CW
    J Clin Lab Immunol; 1998; 50(1):1-16. PubMed ID: 10189612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements.
    Gillespie D; Hubbell HR; Carter WA; Midgette P; Elsasser W; Mullaney R; Strayer DR
    In Vivo; 1994; 8(3):375-81. PubMed ID: 7803722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome.
    Frémont M; El Bakkouri K; Vaeyens F; Herst CV; De Meirleir K; Englebienne P
    Exp Mol Pathol; 2005 Jun; 78(3):239-46. PubMed ID: 15924878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome.
    Snell CR; Vanness JM; Strayer DR; Stevens SR
    In Vivo; 2002; 16(2):107-9. PubMed ID: 12073768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome.
    Nijs J; De Meirleir K
    In Vivo; 2005; 19(6):1013-21. PubMed ID: 16277015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a 2',5'-oligoadenylate (2-5A)-dependent 37-kDa RNase L: azido photoaffinity labeling and 2-5A-dependent activation.
    Shetzline SE; Suhadolnik RJ
    J Biol Chem; 2001 Jun; 276(26):23707-11. PubMed ID: 11323422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of DNA topoisomerase I activity by 2',5'-oligoadenylates and mismatched double-stranded RNA in uninfected and HIV-1-infected H9 cells.
    Schröder HC; Kelve M; Schäcke H; Pfleiderer W; Charubala R; Suhadolnik RJ; Müller WE
    Chem Biol Interact; 1994 Feb; 90(2):169-83. PubMed ID: 8156606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome.
    Shetzline SE; Martinand-Mari C; Reichenbach NL; Buletic Z; Lebleu B; Pfleiderer W; Charubala R; De Meirleir K; De Becker P; Peterson DL; Herst CV; Englebienne P; Suhadolnik RJ
    J Interferon Cytokine Res; 2002 Apr; 22(4):443-56. PubMed ID: 12034027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of poly(I).poly(C12U) and interferon on the multiplication of a mammalian type C retrovirus in human cells.
    Chelbi-Alix MK; Belforte B; Saal F; Lasneret J; Peries J; Thang MN
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2291-7. PubMed ID: 1383406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of the antiretroviral effect of dsRNA.
    Müller WE; Ushijima H; Schröder HC
    Prog Mol Subcell Biol; 1994; 14():66-88. PubMed ID: 7914807
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
    Mitchell WM
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):755-70. PubMed ID: 27045557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Age-dependent changes in "intracellular immunity" to virus infections].
    Schröder HC; Kelve M; Pfeifer K; Flögel-Mrsic M; Müller WE
    Z Gerontol; 1993; 26(4):232-7. PubMed ID: 8212791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.